PMLiVE4d
AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA
AbbVie’s Parkinson’s disease (PD) therapy has been approved by the US Food and Drug Administration (FDA) to treat motor ...
PMLiVE6d
AMICULUM earns EcoVadis silver award for second consecutive year
We are proud to announce that AMICULUM has achieved the silver award from EcoVadis, a global leader in sustainability ...
PMLiVE8d
Innovative Trials appoints new Leadership Team member
Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...
PMLiVE12d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE14d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE12d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...
PMLiVE16d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE14d
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with primary biliary cholangitis (PBC). The oral peroxisome ...
PMLiVE14d
PMLiVE’s T40 – results announced!
The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector has been published. The fifth edition of the list ...
PMLiVE12d
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...
PMLiVE15d
AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra
AstraZeneca (AZ) and Avillion have shared positive results from a phase 3b trial of their inhaled anti-inflammatory rescue medication in asthma patients aged 12 years and older. Airsupra ...
PMLiVE19d
Researchers develop new approach to target cells affected by motor neurone disease
It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...